Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
https://finance.yahoo.com/news/moderna-granted-fda-breakthrough-therapy-121500939.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.